Sharemaestro company-news research for Thermo Fisher Scientific Inc. (TMO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Provisional evidence
Company news sentiment
Latest TMO news and sentiment
Thermo Fisher Scientific Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
25 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone58/100
→
Published 30-day score51/100
Latest source headline
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
finance.yahoo.com · 28 Sep 2026 12:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
25 current stories are mapped specifically to TMO.
The score uses 4 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.073.
Confidence is 20/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
79%/100
Company news25 company stories
98/100
Story agreement2/100 difference
News history
Daily score and story count over 30 days
31 Aug15 Sep29 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.073 after freshness weightingSource breadth80
4 independent publishersCompany relevance79
share tied directly to this companyFreshness52
recency-weighted evidenceAgreement98
how closely stories agreePublisher mix60
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202651MXN 11900.0+5.1%
18 Sep 202651MXN 11320.0+10.5%
11 Sep 202652MXN 10248.69228-0.9%
04 Sep 202651MXN 10338.599107-2.8%
28 Aug 202653MXN 10635.53803-0.8%
21 Aug 202655MXN 10723.306843+5.3%
14 Aug 202659MXN 10186.955103+3.1%
07 Aug 202656MXN 9880.0-0.1%
Provisional evidence
News subjects
What is shaping the score
Market update5314 stories · 56%
Earnings526 stories · 24%
Analyst action563 stories · 12%
Guidance541 stories · 4%
Deals and strategy501 stories · 4%
Source mix
Where the evidence comes from
finance.yahoo.com5212 stories · 48%
simplywall.st503 stories · 12%
MT Newswires602 stories · 8%
MarketBeat581 stories · 4%
The Fly561 stories · 4%
TIKR501 stories · 4%
Simply Wall St.501 stories · 4%
Recurring subjects
Subjects appearing most often
Earnings10Biotech10Pharma6Earnings Growth4Life Sciences3Healthcare3Acquisitions3Semiconductors2Price Target2Market Research Reports2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
24 Jun50 neutral28 Sep 14:54
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 28 Sep 14:54 | 51 | +0 | 23/100 (-1) | 25 (+1) | Provisional |
| 27 Sep 23:59 | 51 | +0 | 24/100 (+6) | 24 (+1) | Provisional |
| 25 Sep 23:59 | 51 | +0 | 18/100 (0) | 23 (+1) | Provisional |
| 24 Sep 23:59 | 51 | +0 | 18/100 (-1) | 22 (+1) | Provisional |
| 23 Sep 23:59 | 51 | +0 | 19/100 (-1) | 21 (+1) | Provisional |
| 22 Sep 23:59 | 51 | +0 | 20/100 (-3) | 20 (-5) | Provisional |
| 19 Sep 23:59 | 51 | +0 | 23/100 (-2) | 25 (+1) | Provisional |
| 18 Sep 23:59 | 51 | -1 | 25/100 (-2) | 24 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 25 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Market update1 story
0.0%51.5%
Earnings2 stories
0.0%44.7%
Analyst action2 stories
0.0%3.8%
Each side uses the same scale: 0–51.5% of the retained directional evidence.
Where the influence comes from
51.5%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
WALTHAM, Mass., September 28, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conf…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
WALTHAM, Mass., September 28, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference call on the same day at 7:00 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com under the subheading "News, Events and Presentations". You can access t
- Published
- 28 Sep 2026 12:00
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial ResultsQuarterly Earnings
57/100 tone
Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in …
50.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as COVID revenue fades and generic and biosimilar competition pressures parts of its older portfolio. DON'T MISS: Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?
- Published
- 27 Sep 2026 22:51
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 41/100
- 30-day weight
- 50.5% of directional evidence · 1.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechEarningsLife SciencesPharmaTurnaround
—Unscored
Market updateNot used in direction
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. Another factor that can influence investors is FOMO, or the fear of missing out, espe…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks. What if you'd invested in Thermo Fisher Scientific (TMO) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today? Thermo Fisher Scientific's Business In-Depth With tha
- Published
- 25 Sep 2026 11:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AcquisitionsBiotechConsensus EstimateEarningsEarnings EstimatePharma
—Unscored
Market updateNot used in direction
Thermo Fisher Scientific (TMO) Launches Gibco CHO K1 Panel On A Fair Value Question
Thermo Fisher Scientific (TMO) has introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at improving cell growth, protein yield, and workflow flexibility for biologics and biosimilars developers. Thermo Fisher Scientific sits at US$665.30 per share after a 30-day …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Thermo Fisher Scientific (TMO) has introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at improving cell growth, protein yield, and workflow flexibility for biologics and biosimilars developers. Thermo Fisher Scientific sits at US$665.30 per share after a 30-day share price return of 5.81%, building on a strong 90-day share price return of 31.55% as launches like the Gibco CHO-K1 Catalog Panel feed into a broader pipeline story. Over a longer horizon, the 1-year total shareholder return of 42.66% and 3-year total shareholder return of 34.82% indicate meaningful gains
- Published
- 24 Sep 2026 10:13
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetBiologicsEarningsEarnings GrowthHealthcarePharma
—Unscored
Market updateNot used in direction
Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
New cGMP-ready media and feed panel helps developers rapidly identify high-performing combinations, with study results demonstrating up to 73% higher titer versus benchmark catalog media and feeds and up to 202% higher peak viable cell density compared with benchmark products tested Key f…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
New cGMP-ready media and feed panel helps developers rapidly identify high-performing combinations, with study results demonstrating up to 73% higher titer versus benchmark catalog media and feeds and up to 202% higher peak viable cell density compared with benchmark products tested Key facts Product: Gibco™ CHO-K1 Catalog Panel Media and Feed Category: Basal and feed media for CHO-K1 cell culture Key benefit: Multiple ready-to-use media and feed options help developers rapidly identify high-performing combinations for CHO-K1 processes Additional benefits: Chemically defined, animal origin-fre
- Published
- 23 Sep 2026 12:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiologicsCell CultureProcess Optimization
—Unscored
Company Logo High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Company Logo High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030. This comprehensive report provides an in-depth a
- Published
- 22 Sep 2026 08:19
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Biomedical ResearchCancer ResearchDrug DiscoveryImaging TechnologiesMarket Research ReportsPersonalized Medicine
—Unscored
Company Logo AI, automation, robotics, microfluidics and nanotechnology are advancing HTS, while personalized medicine, biologics, research funding and pharma-academia partnerships drive demand. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Throughput Screening (HTS) - Global Strategic…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Company Logo AI, automation, robotics, microfluidics and nanotechnology are advancing HTS, while personalized medicine, biologics, research funding and pharma-academia partnerships drive demand. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Throughput Screening (HTS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for High Throughput Screening (HTS) was estimated at US$42.9 Billion in 2024 and is projected to reach US$45.3 Billion by 2030, growing at a CAGR of 0.9% from 2024 to 2030. This comprehensive report provides an in-depth an
- Published
- 22 Sep 2026 08:17
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AutomationBiotechDrug DiscoveryMarket Research ReportsPharmaRobotics
—Unscored
Market updateNot used in direction
¿Está la revisión al alza de las previsiones modificando el argumento de inversión de las acciones de Thermo Fisher (TMO)?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 19 Sep 2026 12:39
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Thermo Fisher Scientific (TMO) is Positioned for Resurgence
Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major indices reached all-time highs, though the energy sector declined. Continued earnings growth, especially among AI-related investments, supported the rally. Technology, particularly semiconductors, led performance as demand for AI infrastructure surged. Despite macroeconomic uncertainties and interest rate infl
- Published
- 18 Sep 2026 14:34
- News subject
- Market update
- Why this score
- Deteriorating financial comparison, Operating growth
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsEarnings GrowthInvestment ManagementLife SciencesSemiconductorsTechnology
—Unscored
Analyst actionNot used in direction
Three Analysts, Three Verdicts on Thermo Fisher: Here’s Who the Numbers Favor
Three Analysts, Three Verdicts on Thermo Fisher: Here's Who the Numbers Favor ©TIKR Key Stats for Thermo Fisher Stock Current Price: $641.39 Target Price (Mid): ~$839 Street Target: ~$645 Potential Total Return: ~31% Annualized IRR: ~7% / year What Happened? Thermo Fisher Scientific (TMO)…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Three Analysts, Three Verdicts on Thermo Fisher: Here's Who the Numbers Favor ©TIKR Key Stats for Thermo Fisher Stock Current Price: $641.39 Target Price (Mid): ~$839 Street Target: ~$645 Potential Total Return: ~31% Annualized IRR: ~7% / year What Happened? Thermo Fisher Scientific (TMO) has become the rare large-cap where three analysts studying the same company cannot agree on direction. On September 3, CLSA started coverage at Outperform with a $748 target. On September 9, UBS upgraded the stock to Buy from Neutral and lifted its target to $730 from $540, a move that came as the firm assum
- Published
- 17 Sep 2026 14:11
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.7d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechEarningsNet IncomePharmaPrice TargetUpgrade Downgrade
—Unscored
Market updateNot used in direction
Why Is Thermo Fisher Scientific (TMO) Building A Massive Early Disease Data Platform?
Thermo Fisher Scientific (NYSE:TMO) and Mayo Clinic announced the formation of Precure, LLC for early disease detection using multi omic data. Precure plans to integrate proteomic, genomic, and longitudinal clinical records into a single biomedical dataset to identify early disease signal…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Thermo Fisher Scientific (NYSE:TMO) and Mayo Clinic announced the formation of Precure, LLC for early disease detection using multi omic data. Precure plans to integrate proteomic, genomic, and longitudinal clinical records into a single biomedical dataset to identify early disease signals. The collaboration positions Thermo Fisher Scientific's technology at the center of large scale healthcare data generation for research and clinical decision support. The Precure, LLC launch is important, but investors should weigh it alongside other Thermo Fisher Scientific risk signals. Our analysis turns
- Published
- 17 Sep 2026 13:11
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechCollaborationHealthcareResearch
58/100 tone
Key Points Interested in Thermo Fisher Scientific Inc.? Here are five stocks we like better. Thermo Fisher raised its outlook after returning to 5% organic growth in the second quarter, with adjusted EPS up 13%. CEO Marc Casper expects about 4% organic growth in 2026 and called it an "out…
35.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Key Points Interested in Thermo Fisher Scientific Inc.? Here are five stocks we like better. Thermo Fisher raised its outlook after returning to 5% organic growth in the second quarter, with adjusted EPS up 13%. CEO Marc Casper expects about 4% organic growth in 2026 and called it an "outstanding year," citing orders running ahead of revenue. Pharma and biotech demand is strengthening as customers invest in drug-development pipelines, AI, and emerging therapies. Recovering biotech funding, mergers and acquisitions, and IPO activity are also supporting spending across clinical research, laborat
- Published
- 17 Sep 2026 10:02
- News subject
- Earnings
- Why this score
- Guidance raised
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 35.7% of directional evidence · 11.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
AcquisitionsBiotechClinical ResearchEarningsEarnings Per ShareGrowth Rate
—Unscored
Market updateNot used in direction
Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 15 Sep 2026 17:16
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear
Pioneering initiative will generate data at the frontier of healthcare to help transform early biological signals into new opportunities for prevention, diagnosis and treatment ROCHESTER, Minn. and WALTHAM, Mass., Sept. 15, 2026 /PRNewswire/ -- Mayo Clinic today announced the launch of Pr…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pioneering initiative will generate data at the frontier of healthcare to help transform early biological signals into new opportunities for prevention, diagnosis and treatment ROCHESTER, Minn. and WALTHAM, Mass., Sept. 15, 2026 /PRNewswire/ -- Mayo Clinic today announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific, the world leader in serving science, to help transform how the life sciences community understands the biological changes that occur as people move from health toward disease.Mayo Clinic Precure, LLC will create one of the world's leading biomedical d
- Published
- 15 Sep 2026 12:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechData AnalyticsDiagnosticsHealthcare InnovationTherapeutics
—Unscored
Market updateNot used in direction
¿Está Thermo Fisher Scientific (TMO) Cara Tras Lanzar Multiskan Ease?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 15 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Analysts See Thermo Fisher at $748 Here’s Where the Stock Could Go
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 11 Sep 2026 15:45
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
58/100 tone
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription?…
10% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 09 Sep 2026 17:55
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 10% of directional evidence · 19.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
56/100 tone
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: UBS upgraded Thermo …
1.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: UBS upgraded Thermo Fisher(TMO) to Buy from Neutral with a price target of $730, up from $540, after a transfer in analyst coverage. Thermo Fisher is positioned for a durable return to 5%-6%-plus organic growth in 2027, supported by improving pharma/biotech funding, bioprocessing demand, reshoring, AI-driven R&D investment, share
- Published
- 09 Sep 2026 13:51
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 1.3% of directional evidence · 19.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechConstruction MaterialsPharmaPrice TargetRevenue Growth
69/100 tone
2.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 09 Sep 2026 13:20
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 2.5% of directional evidence · 19.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Deals and strategyNot used in direction
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher Scientific Inc.'s TMO growth continues to benefit from a broader pickup in customer activity. The company is using acquisitions to move deeper into some of the more attractive corners of the life sciences market while strengthening ties with customers. At the same time, the …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Thermo Fisher Scientific Inc.'s TMO growth continues to benefit from a broader pickup in customer activity. The company is using acquisitions to move deeper into some of the more attractive corners of the life sciences market while strengthening ties with customers. At the same time, the company is improving its debt position while continuing to return cash to shareholders. Yet, a challenging macroeconomic environment and intense competition could weigh on Thermo Fisher's results. In the past year, shares of this Zacks Rank #3 (Hold) company have rallied 6.7% against the 8.2% decline of the in
- Published
- 04 Sep 2026 14:35
- News subject
- Deals and strategy
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AcquisitionsBiotechDebtEarningsEarnings GrowthEarnings Per Share
—Unscored
Market updateNot used in direction
Las acciones de Thermo Fisher Scientific (TMO) parecen estar cerca de su valor razonable tras una subida del 24 %
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Sep 2026 09:47
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.9d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
GuidanceNot used in direction
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Thermo Fisher Scientific Inc. TMO recently unveiled the Thermo Scientific EMPAD G2 detector to help researchers analyze materials in unprecedented detail. This development is expected to bolster the company's Analytical Instruments segment. TMO Stock Outlook Following the News After the a…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Thermo Fisher Scientific Inc. TMO recently unveiled the Thermo Scientific EMPAD G2 detector to help researchers analyze materials in unprecedented detail. This development is expected to bolster the company's Analytical Instruments segment. TMO Stock Outlook Following the News After the announcement, TMO shares dipped slightly by 0.8% last Thursday. On a positive note, Thermo Fisher has steadily ramped up R&D investments in recent years, fueling new product launches and enhancing its portfolio. We expect the latest development to improve investor sentiment toward TMO stock and support its upwa
- Published
- 01 Sep 2026 18:29
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Advanced MaterialsEarningsEarnings GrowthEnergyMedicalSemiconductors
—Unscored
EarningsNot used in direction
Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
WALTHAM, Mass., September 01, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday,…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
WALTHAM, Mass., September 01, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 9:15 a.m. (ET). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to
- Published
- 01 Sep 2026 12:00
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Healthcare
—Unscored
EarningsNot used in direction
Thermo Fisher Scientific (TMO) Unveils New Tools For Electron Microscopy And Isotope Analysis
Thermo Fisher Scientific (NYSE:TMO) introduces the EMPAD G2 detector for high speed, high dynamic range 4D scanning transmission electron microscopy. The company launches Orbitrap Isora and Isora Pro Mass Spectrometers that integrate molecular level isotope ratio analysis. The new instrum…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Thermo Fisher Scientific (NYSE:TMO) introduces the EMPAD G2 detector for high speed, high dynamic range 4D scanning transmission electron microscopy. The company launches Orbitrap Isora and Isora Pro Mass Spectrometers that integrate molecular level isotope ratio analysis. The new instruments target research in material science, environmental studies, geoscience, bioscience, and food authenticity. Consider looking at other stocks developing tools and infrastructure that support advanced research and data intensive science through 56 AI infrastructure stocks.NYSE:TMO Earnings & Revenue Growth a
- Published
- 31 Aug 2026 23:07
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechEarningsLife SciencesMass SpectrometryMicroscopy
—Unscored
Market updateNot used in direction
Thermo Fisher Is Up 23% in a Year. Is It Too Late to Buy at $622?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Aug 2026 18:50
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
TMO news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
23Aug 2026
Premium healthcare stocks often trade at elevated valuations for very different reasons. Thermo Fisher's (NYSE:TMO) investment case increasingly depends on whether the life sciences industry is emerging from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) continues to h…
Article detailsHistorical record
Premium healthcare stocks often trade at elevated valuations for very different reasons. Thermo Fisher's (NYSE:TMO) investment case increasingly depends on whether the life sciences industry is emerging from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) continues to hold a dominant position in robotic surgery through factors such as its highly recurring revenue model. Both companies delivered encouraging quarters, but the market is asking different questions of each. The key issue for investors in this scenario is which premium valuation is better supported by long-term fu
- Published
- 23 Aug 2026 23:15
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BiotechnologyEarningsHealthcareLife SciencesQuarterly ResultsRobotic Surgery
23Aug 2026
Article detailsHistorical record
- Published
- 23 Aug 2026 22:17
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
22Aug 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Thermo Fisher Scientific (TMO) is drawing investor attention after completing Olink Explore HT proteomic analysis on about 5,500 samples from The Michael J. Fox Foundation's Parkins…
Article detailsHistorical record
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Thermo Fisher Scientific (TMO) is drawing investor attention after completing Olink Explore HT proteomic analysis on about 5,500 samples from The Michael J. Fox Foundation's Parkinson's Precision Medicine Initiative. See our latest analysis for Thermo Fisher Scientific. The proteomics update arrives after a strong run in Thermo Fisher Scientific's stock, with the share price at US$629.27 and a 30 day share price return of 19.53%, alongside a 1 year total shareholder return of 26.32% that
- Published
- 22 Aug 2026 16:09
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Balance SheetEarningsHealthcarePharmaShare PriceShareholder
22Aug 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest analyst work on Thermo Fisher Scientific includes a higher Fair Value Estimate that has moved from US$590.77 to US$631.42, a change of a…
Article detailsHistorical record
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest analyst work on Thermo Fisher Scientific includes a higher Fair Value Estimate that has moved from US$590.77 to US$631.42, a change of about 6.9% that feeds directly into refreshed price targets across coverage. This shift sits against a backdrop of mixed optimism and caution, as analysts weigh Q2 strength, sector updates through 2026, and the balance of growth ambition and execution risks. As you read on, you will see how this evolving narrat
- Published
- 22 Aug 2026 14:09
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BiotechEarningsPharmaPrice TargetRatings
22Aug 2026
ArchivedNeutral tone
Thermo Fisher (TMO) Stock Looks Fully Valued Following Its Microbiology Sale
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Thermo Fisher Scientific stock has delivered a strong 26.3% return over the past year, yet the valuation checks suggest the shares are no longer an…
Article detailsHistorical record
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Thermo Fisher Scientific stock has delivered a strong 26.3% return over the past year, yet the valuation checks suggest the shares are no longer an obvious bargain. The Discounted Cash Flow (DCF) estimate points to a level that is close to the current price, while market multiples lean richer. Over the past 12 months Thermo Fisher Scientific has returned 26.3%, which puts more pressure on today's buyers to justify paying up at current levels. Participati
- Published
- 22 Aug 2026 13:08
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Discounted Cash FlowEarningsFree Cash FlowIntrinsic ValueLife SciencesP E Ratio
21Aug 2026
ArchivedNeutral tone
THERMO FISHER SCIENTIFIC, INC.
Article detailsHistorical record
- Published
- 21 Aug 2026 22:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
19Aug 2026
Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how research tools & consumables stocks fared in Q…
Article detailsHistorical record
Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how research tools & consumables stocks fared in Q2, starting with Thermo Fisher (NYSE:TMO). The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through
- Published
- 19 Aug 2026 14:02
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BiotechEarningsEarnings ResultsHealthcarePharmaResearch Tools
12Aug 2026
ArchivedPositive tone
Thermo Fisher Beat Estimates by $300 Million in Q2. Is the Recovery Finally Here?
Article detailsHistorical record
- Published
- 12 Aug 2026 23:27
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
12Aug 2026
ArchivedPositive tone
Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approxim…
Article detailsHistorical record
WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher's Specialty Diagnostics segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260812171039/en/ Contacts Media Contact Information: Sandy Pound Thermo Fisher Scientific Phone: 781-622-1223 E-mail: sandy.pound@thermofisher.com Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1356 E-mail: rafael.tejada@thermofisher.com View Comments
- Published
- 12 Aug 2026 13:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
DIAGNOSTICSM-APHARMA
12Aug 2026
ArchivedPositive tone
Thermo Fisher Beat Estimates by $300 Million in Q2. Is the Recovery Finally Here?
Article detailsHistorical record
- Published
- 12 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
11Aug 2026
ArchivedNeutral tone
Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?
Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmenta…
Article detailsHistorical record
Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Growth Machine Bu
- Published
- 11 Aug 2026 22:20
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
ACQUISITIONSAcquisitionsBALANCE SHEETBalance SheetCLINICAL-TRIALSClinical Trials
11Aug 2026
Olink™ Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approxima…
Article detailsHistorical record
Olink™ Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using Olink technology. Access: The resulting data are available to researchers in PPMI's repository. Purpose: The dataset may help researchers study Parkinson's biology, patient subtypes, disease progression and potential biomarkers. Impact: The resource supports prec
- Published
- 11 Aug 2026 13:30
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BIOMARKERSBiomarkersNEURODEGENERATIVE-DISEASENeurodegenerative DiseasePARKINSONS-DISEASEPRECISION-MEDICINE
10Aug 2026
In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and qu…
Article detailsHistorical record
In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B·R·A·H·M·S, Thermo Fisher is deepening its role in linking high-complexity diagnostics with streamlined lab workflows and more standardized
- Published
- 10 Aug 2026 20:15
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
DIAGNOSTICSDiagnosticsEARNINGSEarningsFDA-APPROVALFda Approval
10Aug 2026
ArchivedPositive tone
Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?
Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies…
Article detailsHistorical record
Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher's (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?Top Long-Term Biotechnology Stocks
- Published
- 10 Aug 2026 01:01
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BIOTECHBiotechEARNINGSEarningsFOURTH QUARTERFourth Quarter
08Aug 2026
ArchivedNeutral tone
Noticias de acciones de Thermo Fisher Scientific Inc (TMO)
Article detailsHistorical record
- Published
- 8 Aug 2026 11:17
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
08Aug 2026
ArchivedNeutral tone
Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.
Article detailsHistorical record
- Published
- 8 Aug 2026 02:13
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
07Aug 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Thermo Fisher CEO Marc Casper sells $8.6m in TMO stock
Article detailsHistorical record
- Published
- 7 Aug 2026 23:52
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
07Aug 2026
ArchivedNeutral tone
Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.
Article detailsHistorical record
- Published
- 7 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
05Aug 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Thermo Fisher Scientific (TMO) Stock Forecast & Analyst Ratings
Article detailsHistorical record
- Published
- 5 Aug 2026 11:50
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
03Aug 2026
Have you evaluated the performance of Thermo Fisher Scientific's (TMO) international operations during the quarter that concluded in June 2026? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in internatio…
Article detailsHistorical record
Have you evaluated the performance of Thermo Fisher Scientific's (TMO) international operations during the quarter that concluded in June 2026? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the
- Published
- 3 Aug 2026 14:15
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Consensus EstimateEarningsFinancialsInternational MarketsRevenueTotal Revenue
03Aug 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Thermo Fisher (TMO) Wins Two FDA Clearances As It Unveils New Diagnostics
Article detailsHistorical record
- Published
- 3 Aug 2026 06:40
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
31Jul 2026
Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. The results prompted several analysts to raise their price targets, but after …
Article detailsHistorical record
Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. The results prompted several analysts to raise their price targets, but after the post-earnings rally, investors must decide whether the recovery story still has room to run.Bernstein Says Life Science Sector is Improving, Resumes Thermo Fisher Scientific (TMO) Coverage Bull Case During the quarter, the company expanded its portfolio with several new analytical instruments, including th
- Published
- 31 Jul 2026 20:09
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BiotechEarningsEarnings GrowthFourth QuarterInstitutional InvestorsLaboratory Equipment
31Jul 2026
ArchivedPositive tone
Thermo Fisher Scientific (TMO) Could Be 2% Undervalued After Q2 Earnings Beat
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Thermo Fisher Scientific (TMO) is back in focus after reporting second quarter results that exceeded market expectations, supported by broad-based demand and fresh regulatory…
Article detailsHistorical record
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Thermo Fisher Scientific (TMO) is back in focus after reporting second quarter results that exceeded market expectations, supported by broad-based demand and fresh regulatory clearances across its diagnostics portfolio. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific's recent earnings beat and steady flow of product clearances have coincided with a 30-day share price return of 15.04% and a 22.92% 90-day share price return. The 1-year total shareholde
- Published
- 31 Jul 2026 00:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Balance SheetBiotechEarningsEarnings GrowthHealthcarePharma
30Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
TMO|Thermo Fisher Scientific Inc|Price:576.670|Chg%:+0.260
Article detailsHistorical record
- Published
- 30 Jul 2026 13:00
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
29Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Thermo Fisher Scientific Inc (TMO) Shares Surge 3.0% -- What GF Score of 85 Tells Investors
Article detailsHistorical record
- Published
- 29 Jul 2026 13:10
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
27Jul 2026
Key facts: Thermo Fisher's specialty diagnostics portfolio addresses high-impact clinical needs across multiple myeloma monitoring with the EXENT® Solution, community oncology testing, critical care, allergy and autoimmune diagnostics, including connective tissue disease testing with the …
Article detailsHistorical record
Key facts: Thermo Fisher's specialty diagnostics portfolio addresses high-impact clinical needs across multiple myeloma monitoring with the EXENT® Solution, community oncology testing, critical care, allergy and autoimmune diagnostics, including connective tissue disease testing with the EliA™ CTD 13 Screen, maternal health, and molecular diagnostics. For clinical and immunoassay laboratories, quality controls are the foundation of every reliable diagnostic result. LabLink360™ software and MAS™ Max quality controls link QC infrastructure to clinical confidence and patient outcomes. From test d
- Published
- 27 Jul 2026 13:30
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Autoimmune DiseaseClinical TrialsDiagnosticsFda ApprovalOncology
27Jul 2026
ArchivedLegacy · tone unscored
Legacy source lookup
Why Thermo Fisher Scientific (TMO) Is Up 6.7% After Q2 Beat, Buyback Completion, And InstaFlux Launch
Article detailsHistorical record
- Published
- 27 Jul 2026 06:40
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
24Jul 2026
Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription?…
Article detailsHistorical record
Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 24 Jul 2026 17:52
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
24Jul 2026
ArchivedPositive tone
Thermo Fisher raises 2026 outlook after 10% growth in Q2
Thermo Fisher Scientific has reported Q2 revenues of $11.99bn, equating to a year-over-year (YoY) growth margin of 10%, prompting the company to raise its 2026 outlook. Besting its Q2 2025 performance of $10.85bn, Thermo Fisher now expects profits for 2026 to fall in the $24.93 to $25.33 …
Article detailsHistorical record
Thermo Fisher Scientific has reported Q2 revenues of $11.99bn, equating to a year-over-year (YoY) growth margin of 10%, prompting the company to raise its 2026 outlook. Besting its Q2 2025 performance of $10.85bn, Thermo Fisher now expects profits for 2026 to fall in the $24.93 to $25.33 per share range, up from $24.64 to $25.12 previously. The life sciences giant is also raising its overall revenue outlook for 2026 to between $47.4bn and $48.1bn, corresponding to a 6%-8% increase over 2025. Thermo Fisher's performance in Q2 at $11.99bn equates to an earnings per share (EPS) ratio of $6.03, ou
- Published
- 24 Jul 2026 12:25
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BiopharmaDivestmentEarningsEarnings Per ShareGuidanceLife Sciences
24Jul 2026
ArchivedPositive tone
Thermo Fisher Scientific (TMO) Reports Strong Q2 2026 Earnings a
* Thermo Fisher Scientific (TMO [https://seekingalpha.com/symbol/TMO]) is scheduled to announce Q2 earnings results on Thursday, July 23rd, before market open. * The consensus EPS estimate is $5.71 [https://seekingalpha.com/symbol/TMO/earnings/estimates] (+6.5% Y/Y) and the consensus reve…
Article detailsHistorical record
* Thermo Fisher Scientific (TMO [https://seekingalpha.com/symbol/TMO]) is scheduled to announce Q2 earnings results on Thursday, July 23rd, before market open. * The consensus EPS estimate is $5.71 [https://seekingalpha.com/symbol/TMO/earnings/estimates] (+6.5% Y/Y) and the consensus revenue estimate is $11.7B (+7.7% Y/Y). * Over the last 2 years, TMO has beaten EPS estimates [https://seekingalpha.com/symbol/TMO/earnings/eps-surprise-summary] 100% of the time and has beaten revenue estimates 88% of the time. * Over the last 3 months, EPS estimates have seen 2 upward revisions [https://seekinga
- Published
- 24 Jul 2026 11:25
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
BiotechEarningsEarnings GrowthEarnings NewsEarnings ResultsFree Cash Flow
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to TMO, but the headline and available text are not mainly about Thermo Fisher Scientific Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of TMO sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.